Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma : a retrospective matched-cohort study
Joint Authors
Zayn al-Din, Ahmad Abd al-Mabud
Id, Salim Muhammad
Darwish, Amirah Diya
Munir, Manar Muhammad
Sad al-Din, Muhammad
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 26, Issue 1 (31 Mar. 2014), pp.1-7, 7 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2014-03-31
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Topics
Abstract EN
Background : Hepatocelluar carcinoma (HCC) is a common cancer worldwide as well as in Egypt with hepatitis B and C, alcohol and aflatoxins being the commonest risk factors.
Tamoxifen was initially reported to confer a marginal survival benefit in advanced HCC.
However, later reports declined any benefit.
Objective : To study the impact of tamoxifen on overall survival (OS) compared to best supportive care (BSC) in Egyptian patients with advanced HCC.
Methods : This retrospective matched-cohort study was conducted at Tanta Cancer Center (TCC), Egypt where 116 advanced HCC cases treated with tamoxifen were compared to TNM stage and Child-Pugh class matched 116 HCC cases who received BSC.
Results : The median OS in the tamoxifen group was 9.3 months (95 % confidence interval [CI], 6.7–11.9 months) compared to 8.7 months (95 %CI, 6.8–10.6) in the BSC group (p = 0.758).
With univariate analyses, it was shown that absence of fatigue, Child-Pugh class A, single tumors, less advanced tumors (T2), and absence of metastases (M0), had significantly better OS than their counterparts.
Multivariate analysis showed that absence of fatigue, Child-Pugh class A and T2 tumors were independent prognostic factors affecting OS.
Tamoxifen produced partial response and clinical stabilization in one % and 16 % of cases, respectively.
The median PFS with tamoxifen was 7.2 months (95 %CI, 5.2–9.5).
Conclusions : Tamoxifen did not show any OS advantage in Egyptian patients with advanced HCC.
Use of this drug is discouraged.
ª 2013 Production and hosting by Elsevier B.V.
on behalf of National Cancer Institute, Cairo University.
American Psychological Association (APA)
Zayn al-Din, Ahmad Abd al-Mabud& Id, Salim Muhammad& Darwish, Amirah Diya& Munir, Manar Muhammad& Sad al-Din, Muhammad. 2014. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma : a retrospective matched-cohort study. Journal of the Egyptian National Cancer Institute،Vol. 26, no. 1, pp.1-7.
https://search.emarefa.net/detail/BIM-365167
Modern Language Association (MLA)
Zayn al-Din, Ahmad Abd al-Mabud…[et al.]. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma : a retrospective matched-cohort study. Journal of the Egyptian National Cancer Institute Vol. 26, no. 1 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-365167
American Medical Association (AMA)
Zayn al-Din, Ahmad Abd al-Mabud& Id, Salim Muhammad& Darwish, Amirah Diya& Munir, Manar Muhammad& Sad al-Din, Muhammad. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma : a retrospective matched-cohort study. Journal of the Egyptian National Cancer Institute. 2014. Vol. 26, no. 1, pp.1-7.
https://search.emarefa.net/detail/BIM-365167
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 7
Record ID
BIM-365167